Reports Q4 revenue $2.96M, consensus $2.2M. "Arcutis’ execution in 2022 was extraordinary, setting us up very well for 2023 and beyond. We are well on our way towards building one of the industry’s leading medical dermatology companies focused on long-term growth from our broad, innovative pipeline," said Frank Watanabe, Arcutis’ President and CEO. "From June to December last year, we delivered four successful pivotal Phase 3 trial readouts, secured an on-time approval for ZORYVE in plaque psoriasis, and raised nearly $300M to bolster a strong balance sheet. The momentum around the ZORYVE psoriasis launch continues to build, with confirmatory feedback on our differentiated product profile and access strategy setting the foundation for commercial success in psoriasis as well as our next three indications."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARQT:
- Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Arcutis Biotherapeutics submits NDA to U.S. FDA for roflumilast foam 0.3%
- Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
- NewAmsterdam appoints John Smither to board of directors
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
